Inspiring transformational change in the

field of oncology diagnostics


To develop and deliver accurate, rapid, minimally

invasive oncology diagnostic products utilising our

patented MCM5 antibodies

Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.

Latest News


- 14 hours ago

Today we are celebrating #BiomedicalScience Day here at #ArquerDiagnostics! Over 70% of diagnoses are based on biom…

- 1 day ago

When we talk about #ADXBLADDER, biomarker & MCM5 technology, you might find it going in one ear & out the other. Vi…